N@N

Market Maker Surveillance Report. IYR, GILD, XLP, NVS, GLW, MSFT, Bearishly Biased Price Friction For Friday, April 8th 2011

^{Published on 2011-04-08 17:52:00 - WOPRAI}
 

April 8, 2011 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 2368 companies with "abnormal" market making, 1988 companies with positive Friction Factors and 3397 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bearish bias) in their stock prices. This means that there was more buying than selling in the stocks and their stock prices dropped. ISHARES DJ US REAL ESTATE (NYSE:IYR), GILEAD SCIENCES INC (NASDAQ:GILD), CONSUMER STAPLES SPDR (NYSE:XLP), NOVARTIS AG-ADR (NYSE:NVS), CORNING INC (NYSE:GLW), MICROSOFT CORP (NASDAQ:MSFT). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

     Symbol     Change       Percent      Buy Volume      Buy %%       Sell Volume     Sell %%      Net Volume      Friction
     IYR        $-0.500      -0.85%       4,823,214       78.14%       2,322,289       37.62%       2,500,925       Abnormal
     GILD       $-0.390      -0.94%       5,152,834       58.56%       3,584,721       40.74%       1,568,113       Abnormal
     XLP        $-0.090      -0.30%       4,447,764       61.01%       2,895,112       39.71%       1,552,652       Abnormal
     NVS        $-0.120      -0.22%       12,074,157      38.35%       10,186,914      32.35%       1,887,243       Abnormal
     GLW        $-0.620      -3.07%       15,056,554      47.52%       12,444,264      39.28%       2,612,290       Abnormal
     MSFT       $-0.200      -0.76%       21,973,019      55.08%       19,522,541      48.94%       2,450,478       Abnormal

For example, the chart above shows IYR with 2,500,925 greater shares of buying than selling (NetVol) and the stock price was down $-0.50000. This means the Market Makers were trading the stock in a way inconsistent with normal supply and demand (Economics 101); more buying than selling should cause prices to rise.

ISHARES DJ US REAL ESTATE (NYSE:IYR) - ISHARE DJ R EST I

GILEAD SCIENCES INC (NASDAQ:GILD) - Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Truvada, Atripla, Viread, and Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amphotericin B liposome injection to treat serious invasive fungal infections; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa that is used for the treatment of chronic angina; Vistide, an antiviral medication that targets cytomegalovirus retinitis in patients with AIDS; and Cayston, an inhaled antibiotic used as a treatment to enhance respiratory systems. The companys products also comprise Tamiflu, an oral antiviral for the treatment and prevention of influenza A and B; Macugen, an intravitreal injection for the treatment of neovascular age-related macular degeneration; and Lexiscan, an injection used as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. Gilead Sciences products under the Phase III clinical trials consist of Ambrisentan, an oral endothelin receptor antagonist for the treatment of idiopathic pulmonary fibrosis and pulmonary hypertension; Elvitegravir, an oral integrase inhibitor being evaluated as part of combination therapy for HIV; and combination of tenofovir disoproxil fumarate, emtricitabine, and TMC278 for the treatment of HIV/AIDS in treatment-naive patients. The companys Phase II clinical trials products comprise Aztreonam, Cicletanine, Cobicistat, combination of elvitegravir, cobicistat, and Truvada, GS 9190, GS 9310/11, and GS 9450, as well as Ranolazine that is preparing for Phase II clinical trials. Its Phase I clinical trials products include GS 6201, GS 9256, GS 9411, and GS 9667. The company was founded in 1987 and is headquartered in Foster City, California.

CONSUMER STAPLES SPDR (NYSE:XLP) - CONSUMER STAP SPD

NOVARTIS AG-ADR (NYSE:NVS) - Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division offers prescription medicines in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; integrated hospital care; and other additional products. The companys Vaccines and Diagnostics division provides preventive vaccines and diagnostic tools. This division sells influenza, meningococcal, pediatric, and traveler vaccines; and blood testing and molecular diagnostics to prevent the spread of infectious diseases. Its Sandoz division provides prescription medicines, as well as pharmaceutical and biotechnological active substances. This division offers active ingredients and finished dosage forms of medicines; active pharmaceutical ingredients and intermediates, primarily antibiotics; protein or biotechnology-based products; and cytotoxic products, as well as provides biotech manufacturing services to other companies. The companys Consumer Health division consists of three business units: over-the-counter medicines (OTC), Animal Health, and CIBA Vision. OTC unit offers readily available consumer medicines. Animal Health unit provides veterinary products for farm and companion animals. CIBA Vision unit manufactures contact lenses and lens care products. It has strategic partnership with Lonza, a Swiss pharmaceuticals manufacturing company. The company was founded in 1895 and is headquartered in Basel, Switzerland.

CORNING INC (NYSE:GLW) - Corning Incorporated manufactures and processes specialty glass and ceramics products worldwide. It operates in five segments: Display Technologies, Telecommunications, Environmental Technologies, Specialty Materials, and Life Sciences. The Display Technologies segment manufactures glass substrates for active matrix liquid crystal displays (LCDs) that are used primarily in notebook computers, flat panel desktop monitors, and LCD televisions. The Telecommunications segment produces optical fiber and cable, and hardware and equipment products, such as cable assemblies, fiber optic hardware, fiber optic connectors, optical components and couplers, closures and pedestals, splice and test equipment, and other accessories for optical connectivity to the telecommunications industry. This segment also offers optical fiber technology products for various applications, such as premises, fiber-to-the-premises access, metropolitan, long-haul, and submarine networks. The Environmental Technologies segment offers ceramic technologies for emissions and pollution control in mobile and stationary applications, including automotive and diesel substrate, and filter products. The Specialty Materials segment manufactures products that provide approximately 150 material formulations for glass, glass ceramics, and fluoride crystals used in commercial and industrial markets. The Life Sciences segment provides general labware and equipment, as well as tools for cell culture and bioprocess, genomics and proteomics, and high-throughput screening. This segment also develops and produces various technologies, such as the Corning HYPERFlask Cell Culture Vessel for increased cell yields; and other novel surfaces, which include the Corning CellBIND Surface and the Corning Osteo-Assay surface. The company was formerly known as Corning Glass Works and changed its name to Corning Incorporated in April 1989. Corning Incorporated was founded in 1851 and is based in Corning, New York.

MICROSOFT CORP (NASDAQ:MSFT) - Microsoft Corporation develops, manufactures, licenses, and supports a range of software products and services for various computing devices worldwide. The companys Windows & Windows Live Division segment offers Windows operating system, Windows Live, and Internet Explorer. It offers Windows operating system, which include Windows 7, Windows Vista, and Windows XP Home, as well as Windows Live suite of applications and Web services. Microsofts Server and Tools segment provides Windows Server operating systems, Windows Azure, Microsoft SQL Server, SQL Azure, Visual Studio, Silverlight, System Center products, Biz Talk server, Microsoft consulting services, and product support services. This segment also provides enterprise consulting and product support services; and training and certification to developers and information technology professionals, as well as builds standalone and software development lifecycle tools for software architects, developers, testers, and project managers. The companys Online Services Division segment offers online information products, such as Bing, MSN portals, and channels; and an online advertising platform for publishers and advertisers. Microsofts Microsoft Business Division segment offers Microsoft Office, Microsoft SharePoint, and Microsoft Dynamics ERP and CRM, as well as Microsoft Office Web Apps. The companys Entertainment and Devices Division segment develops, produces, and markets the Xbox 360 platform; PC software games; online games and services; Mediaroom, an Internet protocol television software; Windows Phone and Windows Embedded device platforms; the Zune digital music and entertainment platform; and application software for Apples Macintosh computers, Microsoft PC hardware products, and other devices. This segment also involves in retail and marketing of packaged versions of the Microsoft Office system and the Windows operating systems. Microsoft was founded in 1975 and is headquartered in Redmond, Washington.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net